{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":51,"n_cols":5,"rows_kept":51,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[12,2,12,3],[13,2,13,3],[16,2,16,3],[24,2,24,3],[24,4,24,5],[25,2,25,3],[25,4,25,5],[26,2,26,3],[26,4,26,5],[27,2,27,3],[28,2,28,3],[32,2,32,3],[33,2,33,3],[34,2,34,3],[35,2,35,3],[37,2,37,3],[41,2,41,3],[42,2,42,3],[46,2,46,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910786623203321"]
[null,null,"Titolo",null,"WHO Expert Committee on Specifications for Pharmaceutical Preparations : forty-eighth meeting report / / World Health Organization"]
[null,null,"Pubbl/distr/stampa",null,"Geneva, Switzerland : , : World Health Organization, , 2014"]
[{"$nulls":4},"©2014"]
[null,null,"ISBN",null,"92-4-069254-1"]
[null,null,"Descrizione fisica",null,"1 online resource (401 p.)"]
[null,null,"Collana",null,"WHO Technical Report Series ; ; 986"]
[null,null,"Disciplina",null,"615.1"]
[null,null,"Soggetti",null,"Drugs - Specifications"]
[{"$nulls":4},"Drugs - Standards"]
[{"$nulls":4},"Pharmaceutical preparations - Standards"]
[{"$nulls":4},"Pharmaceutical technology - Standards"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,"Nota di contenuto",null,"Cover; Contents; WHO Expert Committee on Specifications for Pharmaceutical Preparations; 1. Introduction; 2. General policy; 2.1 Cross-cutting pharmaceutical quality assurance issues; 2.1.1 Update from the Expert Committee on the Selection and Use of Essential Medicines; 2.1.2 Update from the Expert Committee on Biological Standardization; 2.1.3 Temperature mapping of a storage area; 2.2 International collaboration; 2.2.1 Collaboration with international organizations and agencies; 2.2.2 Pharmacopoeial Discussion Group"]
[{"$nulls":4},"2.2.3 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)2.2.4 International Conference of Drug Regulatory Authorities; 3. Quality control - specifications and tests; 3.1 The International Pharmacopoeia; 3.1.1 Monographs under elaboration; 3.1.2 Monographs proposed for elaboration or withdrawal from The International Pharmacopoeia; 3.2 Specifications for medicines, including children's medicines; 3.2.1 Maternal, newborn, child and adolescent health medicines; 3.2.2 Antimalarial medicines; 3.2.3 Antiviral medicines"]
[{"$nulls":4},"3.2.4 Antituberculosis medicines3.2.5 Medicines for neglected tropical diseases; 3.2.6 Other anti-infective medicines; 3.2.7 Other medicines; 3.3 General monographs for dosage forms and associated method "]
[{"$nulls":4},"texts; 3.3.1 Supplementary information; 3.3.2 Reagents, test solutions and volumetric solutions; 3.3.3 General policy; 3.3.4 Radiopharmaceuticals; 4. Quality control - International Reference Materials (International Chemical Reference Substances and Infrared Reference Spectra); 4.1 Update on International Chemical Reference Substances; 4.1.1 Overview"]
[{"$nulls":4},"4.1.2 Release procedure for International Chemical Reference Substances4.1.3 Report from the ICRS Board; 4.1.4 Draft chapter on reference substances and reference spectra for the Supplementary information section of The International Pharmacopoeia; 4.1.5 International Chemical Reference Substances - miscellaneous topics; 4.2 Report of the custodian centre for ICRS; 4.2.1 Annual report; 4.2.2 Update on the annual report; 5. Quality control - national laboratories; 5.1 External Quality Assurance Assessment Scheme; 5.1.1 Final report on EQAAS 5.6; 5.1.2 Preliminary report on EQAAS 5.7"]
[{"$nulls":4},"5.1.3 EQAAS Phase 6 proposals5.2 Networking; 5.3 Training materials for quality control laboratories and microbiological laboratories; 6. Quality assurance - good manufacturing practices; 6.1 Updates of WHO good manufacturing practices; 6.2 Update of WHO good manufacturing practices: validation; 6.3 General guidance for inspectors on \"hold-time\" studies; 6.4 Training materials; 7. Quality assurance - new initiatives; 7.1 International meetings of world pharmacopoeias; 7.2 Good pharmacopoeial practices; 7.3 FIP-WHO technical guidelines; 7.4 Screening technologies for \"suspect\" medicines"]
[{"$nulls":4},"7.5 Laboratory functions survey regarding testing of spurious/falsely-labelled/falsified/counterfeit medical products"]
[null,null,null,"Sommario/riassunto","The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear independent and practical standards and guidelines for the quality assurance of medicines. Standards are developed by the Committee through worldwide consultation and an international consensus-building process. The following new guidelines were adopted and recommended for use in addition to 20 monographs and general texts for inclusion in The International Pharmacopoeia and 11 new International Chemical Reference Substances. The International Pharmacopoeia - updating mechanism for the section on radioph"]
[null,"2.","Record Nr.",null,"UNINA9910970083003321"]
[null,null,"Autore",null,"Okoye Ngozi Vivian"]
[null,null,"Titolo",null,"Behavioural risks in corporate governance : regulatory intervention as a risk management mechanism / / Ngozi Vivian Okoye"]
[null,null,"Pubbl/distr/stampa",null,"London ; ; New York : , : Routledge, , 2015"]
[null,null,"ISBN",null,"1-317-70140-2"]
[{"$nulls":4},"1-138-09434-X"]
[{"$nulls":4},"1-315-78007-0"]
[{"$nulls":4},"1-317-70141-0"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (286 p.)"]
[null,null,"Collana",null,"Routledge Research in Corporate Law"]
[null,null,"Disciplina",null,"346.410664"]
[{"$nulls":4},"658.42"]
[null,null,"Soggetti",null,"Corporate governance - Law and legislation - Great Britain"]
[{"$nulls":4},"Corporate governance - Law and legislation - United States"]
[{"$nulls":4},"Directors of corporations - Conduct of life"]
[{"$nulls":4},"USA"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references at the end of each chapters and index."]
[null,null,"Nota di contenuto",null,"Cover; Title Page; Copyright Page; Table of Contents; Table of cases; Table of legislation; Table of codes, guidelines and guidance; List of figures; Acknowledgements; 1 Introduction; 1.1 Background and overview; 1.2 Research paradigm and methodology; 2 A discussion of relevant literature; 2.1 Introduction; 2.2 Corporate theories; 2.3 Corporate governance; 2.4 The corporate board and company directors; 2.5 Corporate failures; 2.6 Personality and behaviour; 2.7 Corporate risk and risk management; 2.8 Regulatory theories; 2.9 Conclusion; 3 Risk and corporate governance; 3.1 Introduction"]
[{"$nulls":4},"3.2 Risk3.3 Risk management; 3.4 Risk, personality and behavioural risk in corporate governance; 3.5 The UK Corporate Governance Code; 3.6 UK Companies Act; 3.7 Other regulations/corporate mechanisms; 3.8 Conclusion; 4 Impact of behavioural risks in corporate governance; 4.1 Introduction; 4.2 Investigations and reports; 4.3 The behaviour of company directors in corporate failures; 4.4 Judicial and societal perspectives; 4.5 Consequential issues; 4.6 Conclusion; 5 Personality and corporate governance; 5.1 Introduction; 5.2 What is personality?; 5.3 The Five-Factor Model of personality"]
[{"$nulls":4},"5.4 Identification of personality dimensions5.5 Personality traits and corporate governance; 5.6 Personality traits and specific job performance; 5.7 Conscientiousness; 5.8 Conclusion; 6 Conceptual framework for personality risk management; 6.1 Introduction; 6.2 What needs to be done?; 6.3 Approaches to managing personality risks; 6.4 Indicators of effectiveness; 6.5 Why choose a regulatory regime?; 6.6 Corporate and regulatory theories in the management of personality risks; 6.7 Aims of the personality risk management model; 6.8 Conclusion; 7 The model; 7.1 Preliminary issues"]
[{"$nulls":4},"7.2 The model in detail7.3 The model and the present UK behavioural risk management mechanisms: limitations in the status quo; 7.4 Practical importation of the model into the present UK regime; 7.5 Considerations in relation to the model; 7.6 Conclusion; 8 Conclusion; 8.1 Overview of arguments; 8.2 Recommendations for future research and development; Index"]
[null,null,null,"Sommario/riassunto","Recent cases of corporate failures, including the fixing of LIBOR rates and money laundering issues in the banking industry, highlight how behavioural issues on the part of company directors are significant contributory factors in corporate governance and the success or failure of companies. This book examines how personality and behavioural issues have contributed to major corporate failures, and how this risk may be managed.The book examines behavioural risks in corporate governance, and evaluates the extent to which risk management mechanisms have acknowledged various aspects of behaviour."]